

# **Pediatric Central IRB Meeting Agenda**

# Friday, April 21, 2017 11:00am – 3:00 pm Eastern Time Agenda

### I. General Business

• Next Meeting Date: Thursday, May 11, 2017

## II. Initial Review

**APEC1621A**, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of LOX\_101 (Larotrectinib) in Patients with Tumors Harboring Actionable NTRK Fusions (Protocol Version Date 03/10/17)

#### III. Initial Review

**APEC1621C,** NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Tazemetostat in Patients with Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex (Protocol Version Date 03/24/17)

#### IV. Initial Review

**APEC1621D**, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Ly3023414 in Patients with Solid Tumors (Protocol Version Date 03/24/17)

# V. Initial Review

**APEC1621E**, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol pf Selumetinib (AZD6244 Hydrogen Sulfate) in Patients with Tumors Harboring Activating MAPK Pathway Mutations (Protocol Version Date 03/07/17)